Gaucher Disease Clinical Trials and Treatments

Gaucher disease is the most common lysosomal storage disorder, caused by autosomal recessive mutations in the GBA gene affecting glucocerebrosidase enzyme activity. Without adequate enzyme function, glucocerebroside accumulates within macrophages throughout the body, creating characteristic "Gaucher cells." Type 1 disease (non-neuropathic, the most common form) manifests primarily with hepatosplenomegaly, bone disease, and hematologic abnormalities including anemia and thrombocytopenia, but typically does not affect the central nervous system. Patients experience debilitating bone pain, increased fracture risk, severe fatigue, and bleeding complications.

The most common symptoms of Gaucher Disease include Severe bone pain, especially in femur and tibia, Enlarged spleen and liver, Fatigue and anemia, Easy bruising and nosebleeds from low platelets, Delayed puberty and growth failure, among others. Gaucher Disease affects approximately 1 in 40,000 to 60,000 in general population; 1 in 850 among Ashkenazi Jewish population. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Gaucher Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Gene therapy and improved disease-modifying therapies are opening new horizons for Gaucher disease management. Clinical trials continue evaluating gene therapy approaches, next-generation enzyme replacement formulations, and novel substrate reduction inhibitors that may offer improved efficacy, dosing convenience, or better tolerability.

Yes. As of October 21, 2026, 5 FDA-approved medicines have a current label that names Gaucher Disease: Cerdelga (eliglustat), first approved in 2014; Cerezyme (imiglucerase), first approved in 1994; Elelyso (taliglucerase alfa), first approved in 2012; VPRIV (velaglucerase alfa), first approved in 2010; and Zavesca (miglustat), first approved in 2003. Corticosteroids and immune globulins count once each. The FDA is due to decide on Venglustat by November 25, 2026; the FDA calendar page carries the outcome the day it lands.

Gaucher Disease is caused by variants in the GBA1 gene. All types (1, 2, 3) are caused by biallelic GBA1 variants; enzyme assay plus GBA1 sequencing confirms the diagnosis.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child. The condition affects approximately 1 in 40,000 to 60,000 in general population; 1 in 850 among Ashkenazi Jewish population. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Gaucher Disease looks at the GBA1 gene. All types (1, 2, 3) are caused by biallelic GBA1 variants; enzyme assay plus GBA1 sequencing confirms the diagnosis.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Gaucher Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Gaucher Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.